Medical Science Liaison - Dallas/Fort Worth TX
Gilead Sciences- Full Time
- Junior (1 to 2 years)
Dyno Therapeutics
Candidates must possess an advanced scientific degree, such as an MD, PhD, NP, PharmD, or PA, and a minimum of 8 years of experience as a Medical Science Liaison. Preferred experience includes clinical expertise in neuromuscular disorders, particularly DMD and DM1, and rare disease experience is considered. Strong knowledge of investigational products and the neuromuscular space, including emerging data, is required, along with an understanding of clinical trial and investigator-sponsored study processes.
The Associate Director, Medical Science Liaison will build awareness of the company within the medical community and develop strategic KOL/territory engagement plans, support clinical research and speaker development, demonstrate thorough knowledge of the company’s portfolio, maximize conference attendance, collaborate cross-functionally to advance business and scientific goals, lead KOL engagement strategies, establish and develop HCP relationships through data discussions and addressing patient journey barriers, respond to information requests compliantly, manage administrative tasks, and leverage neuromuscular relationships to support study enrollment.
Develops AI-optimized gene therapy vectors
Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.